 CAMBRIDGE, Mass., June 11, 2021 GLOBE NEWSWIRE -- Constellation Pharmaceuticals, Inc. Nasdaq: CNST, a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that three posters relating to the MANIFEST clinical trial of pelabresib CPI-0610 in myelofibrosis MF were published online in association with the European Hematology Association EHA annual meeting. The data in these posters are based on a data cutoff of September 29, 2020 from the MANIFEST Phase 2 clinical trial and reflect an analysis of pelabresib clinical and translational activity. 